$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > CAPItello-291

卡匹色替|上市信息

Truqap与芙仕得联用在欧盟获批用于治疗晚期 ER 阳性乳腺癌患者
Truqap (capivasertib) 联合芙仕得在美国获批用于HR 阳性晚期乳
卡匹色替获批中国上市!精准狙击耐药靶点,为CDK4/6i经治HR+/HER2-乳

卡匹色替|最新研究

刘强教授:CAPItello-291研究PFS2、TFSC结果公布,Capivasertib助力